A recent study highlighted its association with tumor-infiltrating immune cells: elevated CDKN2A expression is linked to increased infiltration by activated B cells and CD4+ T cells, indicating a better prognosis, while its reduced expression is associated with greater neutrophil infiltration, suggesting a worse outcome (18). The gene discussed is CDKN2A; the disease is neoplasm.